在政策支持、市场推动下，近年来各地企业申报绿色工厂积极性不断提升，2024年全国新增国家级 绿色工厂1382家，累计达6430家，带动地方累计梯度培育省市层面绿色工厂1.6万余家。 "获得国家级绿色工厂认证，相当于手持一张权威的绿色名片，有助于企业在市场中脱颖而出，吸 引更多认可绿色低碳生产的客户。"英发睿能总裁办ESG部长蒲易告诉中国证券报记者。 蒲易发现，2025年的绿色工厂申报流程呈现出更为简便的特征，例如《通知》提到，企业登录工业 节能与绿色发展管理平台，如实自主填报申报表完成自评价，不再需要提交第三方评价报告。"这帮助 企业降低了申报的经济成本和时间成本。"蒲易说。 复洁环保控股子公司捷碳科技为企业提供绿色改造、绿色工厂申报服务。捷碳科技负责人顾纯俊告 诉记者："今年绿色工厂申报首次取消了第三方评价报告，采用直接线上填报，管理平台提供政策解读 和填报说明视频，流程更加高效，操作更便捷、透明。" 绿色工厂评级指标也大幅度简化。《通知》附件显示，新的绿色工厂评价要求包括五项一级指标， 分别是能源低碳化、资源高效化、生产洁净化、产品绿色化、用地集约化。五项一级指标下设14项二级 指标。"二级指标数量从之前 ...

证券时报·数据宝统计，截至今日下午14:00，上证综指3996.35点，收于年线之上，跌幅为0.16%，A股 总成交额为16020.79亿元。到目前为止，今日有32只A股价格突破了年线，其中乖离率较大的个股有曼 恩斯特、亚辉龙、宣亚国际等，乖离率分别为5.00%、4.97%、4.31%；健麾信息、中国石化、翔港科技 等个股乖离率较小，刚刚站上年线。 | 002194 | 武汉凡 | 1.07 | 4.93 | 13.13 | 13.25 | 0.90 | | --- | --- | --- | --- | --- | --- | --- | | | 谷 | | | | | | | 300439 | 美康生 | 1.12 | 2.02 | 10.76 | 10.85 | 0.79 | | | 物 | | | | | | | 605266 | 健之佳 | 1.31 | 2.06 | 21.56 | 21.71 | 0.71 | | 688198 | 佰仁医 | 2.22 | 0.44 | 110.56 | 1 11.25 | 0.63 | | | 疗 | | | | | | | 605589 | 圣泉集 | 0. ...

华宝中证医疗ETF（512170）成立日期2019年5月20日，最新规模264.04亿。今年以来收益11.75%，同 类排名3563/4216；近一年亏损0.98%，同类排名3661/3937；成立以来收益9.51%。 华宝中证医疗ETF（512170）基金经理为胡洁。 截至发稿，胡洁累计任职时间13年31天，现任基金资产总规模1002.04亿元，任职期间最佳基金回报 184.02%， 任职期间最差基金回报-98.01%。 11月12日，亚辉龙涨5.21%，截至发稿，报16.15元/股，成交1.59亿元，换手率1.77%，总市值92.12亿 元。 资料显示，深圳市亚辉龙生物科技股份有限公司位于广东省深圳市龙岗区宝龙街道宝龙二路亚辉龙生物 科技厂区1栋，成立日期2008年9月17日，上市日期2021年5月17日，公司主营业务涉及以化学发光免疫 分析法为主的体外诊断仪器及配套试剂的研发、生产和销售,及部分非自产医疗器械产品的代理销售业 务。主营业务收入构成为：自产试剂(非新冠产品)58.57%，自产耗材(非新冠产品)12.60%，自产仪器(非 新冠产品)11.92%，代理试剂11.02%，代理耗材3.30%，其他 ...

Core Viewpoint - Recently, the company received a medical device registration certificate issued by the National Medical Products Administration for its product, the Human Chorionic Gonadotropin and β Subunit Determination Kit (Chemiluminescence Method) [2] Company Summary - The product is designed for the determination of human chorionic gonadotropin and its β subunit, indicating its application in medical diagnostics [2] - The approval from the regulatory authority signifies a potential expansion in the company's product offerings and market reach [2] Industry Summary - The announcement reflects ongoing developments in the medical device sector, particularly in diagnostic tools [2] - Regulatory approvals are crucial for companies in the healthcare industry, as they can lead to increased market opportunities and revenue growth [2]

证券代码：688575 证券简称：亚辉龙 公告编号：2025-058 深圳市亚辉龙生物科技股份有限公司 关于自愿披露取得医疗器械注册证的公告 人绒毛膜促性腺激素（HCG）是由胎盘滋养层细胞分泌的一种异二聚体糖蛋白，包 含 92 个氨基酸组成的α亚基和 145 个氨基酸组成的β亚基，分子量为 37 kDa。其α亚 基与促甲状腺激素（TSH），促黄体生成素（LH），促卵泡激素（FSH）的α亚基相同， 而β亚基各不相同，赋予激素生物学和免疫学特异性。HCG 在产生、分泌和代谢过程中， 会发生断裂、离解等变化，而以多种不同的形式存在，血液中形式包括完整 HCG、缺口 HCG、完整游离α亚基、大分子游离α亚基、完整游离β亚基、缺口游离β亚基、β亚 基羧基末端丢失的 HCG，在尿中则存在β核心片段。正常妊娠时，完整 HCG 在受精后 7 天左右可在母体检测到，其后呈指数增长，至妊娠 9～11 周达到高峰，妊娠 3 个月后显 著降低，且异位妊娠比宫内孕完整 HCG 明显降低，HCG 检测临床上用于异位妊娠、早孕 的辅助诊断。HCG 的异常升高还常见于妊娠滋养细胞疾病、睾丸癌、膀胱癌等恶性肿瘤。 绒毛膜癌是一种恶性滋养层细胞 ...

Core Insights - The company, Aihuilong (688575.SH), has received a medical device registration certificate from the National Medical Products Administration for its Human Chorionic Gonadotropin (HCG) and β Subunit Assay Kit (Chemiluminescence Method) [1][3] - The product is intended for in vitro quantitative measurement of HCG and its β subunit in human serum and/or plasma, primarily for dynamic monitoring of malignant tumor patients to assist in assessing disease progression or treatment efficacy [1][2] Product Details - HCG is a glycoprotein hormone secreted by trophoblast cells of the placenta, consisting of an α subunit and a β subunit, with a molecular weight of 37 kDa [2] - The hormone exists in various forms in the blood, including intact HCG, free α subunit, and free β subunit, and is used clinically for diagnosing ectopic pregnancy and early pregnancy [2] - Abnormal elevation of HCG is often associated with malignant tumors such as testicular cancer and bladder cancer, with β-HCG being a valuable marker for monitoring trophoblastic diseases [2] Company Developments - The company has obtained a total of 172 domestic medical device registration certificates for chemiluminescence reagents, contributing to a total of 249 registrations [3] - The recent registration enhances the company's automated chemiluminescence product line and expands its testing portfolio in reproductive hormones and tumor markers [3]

Core Viewpoint - The company has received a medical device registration certificate from the National Medical Products Administration for a new product, enhancing its product line in the field of reproductive hormones and tumor markers [1] Product Development - The newly approved product is a human chorionic gonadotropin and β-subunit assay kit (chemiluminescence method) for the quantitative determination of human chorionic gonadotropin and β-subunit levels in human serum and/or plasma [1] - This product enriches the company's fully automated chemiluminescence product line [1] Market Impact - The sales performance of the new product will be influenced by market conditions, making it difficult for the company to predict its impact on future performance [1]

Core Viewpoint - The company, Aihuilong (688575.SH), has received a medical device registration certificate from the National Medical Products Administration for its product, which is a kit for the quantitative determination of human chorionic gonadotropin and its beta subunit in serum or plasma [1] Group 1 - The product is intended for in vitro quantitative measurement of human chorionic gonadotropin and its beta subunit levels in human serum and/or plasma [1] - It is primarily used for dynamic monitoring of malignant tumor patients to assist in assessing disease progression or treatment effectiveness [1] - The product is not intended for early diagnosis or confirmation of malignant tumors and is not used for tumor screening in the general population [1]

智通财经APP讯，亚辉龙(688575.SH)发布公告，公司于近日收到了由国家药品监督管理局签发的医疗 器械注册证，产品名称：人绒毛膜促性腺激素及β亚单位测定试剂盒(化学发光法)。该产品用于体外定 量测定人血清和(或)血浆中人绒毛膜促性腺激素及β亚单位的含量。主要用于对恶性肿瘤患者进行动态 监测以辅助判断疾病进程或治疗效果，不能作为恶性肿瘤早期诊断或确诊的依据，不用于普通人群的肿 瘤筛查。 ...

Group 1 - Company MengTian Home is planning to acquire control of ChuanTu Microelectronics through a combination of issuing shares and cash payment, which is expected to constitute a major asset restructuring [1] - The actual controller of MengTian Home, Yu Jingyuan, is also planning a transfer of control, which is independent of the aforementioned acquisition [1] - The stock of MengTian Home has been suspended since November 6, 2025, with an expected suspension period of no more than 10 trading days [1] Group 2 - Kweichow Moutai plans to repurchase shares with an investment of between 1.5 billion and 3 billion RMB, with a maximum repurchase price of 1,887.63 RMB per share [2] - The repurchase will be conducted through centralized bidding and will be used for cancellation to reduce the company's registered capital [2] - The company also plans to distribute a cash dividend of 23.957 RMB per share, totaling approximately 30 billion RMB based on the total share capital as of September 30, 2025 [2] Group 3 - JiaYuan Technology has signed a cooperation framework agreement with CATL to deepen their long-term procurement cooperation in the supply, research, and production of materials for new battery anodes [3] - The agreement aims to enhance collaboration in technology research and market expansion, benefiting both companies [3] - JiaYuan Technology will be the preferred supplier for new products developed in cooperation with CATL, which will strengthen its competitive position in the industry [3] Group 4 - KaBeiYi has invested 100 million RMB to establish a wholly-owned subsidiary, Shanghai KaBeiYi Robotics, to accelerate the development of humanoid robot components [4] - The new subsidiary will operate independently and is expected to enhance the company's investment in humanoid robotics [4] Group 5 - Bertley has established a joint venture, Wuhu Bertley Drive Technology Co., Ltd., with a registered capital of 100 million RMB, where Bertley holds a 60% stake [5] - The joint venture will focus on the research, production, and sales of various electric motors, aligning with the company's strategy for technological autonomy and product diversification [5] - This strategic move is aimed at strengthening the company's position in high-growth sectors such as new energy vehicles and humanoid robotics [5] Group 6 - Tongling Nonferrous Metals has successfully acquired exploration rights for the JiGuangShan-HuVillage copper-gold-molybdenum mine for 3.204 billion RMB [6] - Ningbo Port expects to achieve a container throughput of 4.56 million TEUs in October 2025, representing a year-on-year increase of 12.4% [6] - Hongquan Technology will change its stock name to Hongquan Technology starting November 11, 2025, while maintaining its full name and stock code [6] Group 7 - Dongfeng Group has undergone a change in its controlling shareholder and actual controller, leading to a name change to Quzhou Dongfeng New Materials Group Co., Ltd. [7] - Yihong Long has been recognized as a national manufacturing single champion enterprise for its self-immune disease diagnostic products [7] Group 8 - China Shipbuilding Technology's subsidiary plans to publicly transfer 100% equity of a clean energy development company as part of its strategy to enhance operational quality and fund future projects [8] - HeimuDan's subsidiary is selling its developed digital economy industrial park properties for approximately 41.97 million RMB [8] Group 9 - Shenkai Co. has completed the transfer of shares from its original controlling shareholder to Shenzhen Huili Hongsheng Industrial Holdings, changing its controlling shareholder [9] - Luzhou Laojiao is investing approximately 1.478 billion RMB to build a historical and cultural industry park to enhance brand influence [9] Group 10 - Xiling Power has signed a share purchase agreement to acquire 100% of Weipai Automotive Electronics, which specializes in turbocharger production [10] - Mind Electronics plans to divest its 51% stake in a subsidiary for 14.8 million RMB to focus on core business development [10] Group 11 - Triangle Defense has signed development and framework order agreements with Siemens Energy to supply specific items, enhancing its international market presence [11] Group 12 - Hualan Co.'s controlling shareholder plans to increase its stake in the company by investing between 30 million and 60 million RMB [12] - Key executives of Kaili Medical have also increased their stakes in the company through market transactions [12]